Contact | 
Print version | 
PDF version | 
Send article | 
RSS feed
DakoCytomation and Epitomics announce license and development agreement concerning rabbit monoclonal antibodies
19 Oct 2004 -
DakoCytomation A/S, the leading global provider of in vitro diagnostic systems for Anatomic Pathologists, announced it entered into a license and a development agreement with Epitomics, Inc, the founder of rabbit monoclonal antibody technology. Terms of the license agreement grant DakoCytomation worldwide commercial rights to rabbit monoclonal antibodies currently developed by Epitomics. Additionally, under the development agreement Epitomics will design novel rabbit monoclonal antibodies for DakoCytomation to globally commercialize on a co-exclusive basis.
DakoCytomation's CEO Jes Ostergaard is enthusiastic about this partnership, stating, "The collaboration with Epitomics gives us access to a new technology that is tailored to supplement our existing portfolio of high quality antibodies. The more of these technologies that we have access to, the better system solutions we can provide for our customers in the Pathology Laboratories".
"In keeping with our corporate objectives, we will aggressively deploy the technologies that are necessary to expand our offerings and strengthen our ability to provide the best and most reliable tests worldwide. However, the quality and consistency of our primary antibodies remains the foundation on which we base our systems. We feel that this agreement is an opportunity to further strengthen our capabilities in this fundamental area" says Dennis Chenoweth, Corporate Vice President of Diagnostics.
DakoCytomation is eager to utilize its strong market knowledge as well as its extensive distribution and customer network to provide the global diagnostics community with cutting edge reagents such as rabbit monoclonal antibodies. Epitomics' unique high performance and high quality rabbit monoclonal antibodies will greatly augment DakoCytomation's broad portfolio of high quality reagents for in vitro diagnostics.
"The collaboration with DakoCytomation once again demonstrates the market acceptance of Epitomics robust rabbit monoclonal antibody technology," said Epitomics' CEO Dr. Guo-Liang Yu. "We are looking forward to seeing the utilization of our technology to benefit doctors and patients through the collaborations like the ones we have had with DakoCytomation."
Top
